Search

Your search keyword '"Mosenzon, Ofri"' showing total 708 results

Search Constraints

Start Over You searched for: Author "Mosenzon, Ofri" Remove constraint Author: "Mosenzon, Ofri"
708 results on '"Mosenzon, Ofri"'

Search Results

103. Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial

104. Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.

105. Obesity and effects of dapagliflozin on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus in the DECLARE–TIMI 58 trial.

109. Asthma in Youth and Early-onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents

111. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes

112. 990-P: Use of Glucose-Lowering Agents According to Cardiovascular Risk Factors in People with T2D and with or without CVD in the CAPTURE Study

113. Abstract #1003901: Once-Weekly Subcutaneous Semaglutide 2.4 mg Plus Intensive Behavioral Therapy Produces Clinically Meaningful Weight Loss in Adults with Overweight/Obesity Regardless of Baseline Characteristics and Weight History

115. 788-P: The Cardiovascular and Renal Benefits of Dapagliflozin Are Independent of Baseline HbA1c: Analyses from DECLARE-TIMI 58

116. 974-P: Associations between Patient Characteristics and Cardiovascular Disease: A Post-hoc Analysis from the CAPTURE Study

117. Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood

120. MEDIATION ANALYSIS FOR DAPAGLIFLOZIN AND THE REDUCTION IN HOSPITALIZATION FOR HEART FAILURE IN DECLARE-TIMI 58

123. Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4)

124. Additional file 1 of CAPTURE: a multinational, cross-sectional study of cardiovascular disease prevalence in adults with type 2 diabetes across 13 countries

125. Asthma & Type 2 Diabetes - Supplementary Appendix.pdf

126. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial

127. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes:A Post Hoc Analysis of the LEADER Trial

129. Anti-interleukin-21 antibody and liraglutide for the preservation of β-cell function in adults with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled, phase 2 trial

130. Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

131. Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease

132. Cardiovascular and renal outcomes by baseline albuminuria status and renal function:Results from the LEADER randomized trial

133. Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

134. The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial

135. Stuttering and Incident Type 2 Diabetes: A Population-Based Study of 2.2 Million Adolescents

136. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium–glucose co‐transporter 2 inhibitor therapy in DECLARE‐TIMI 58

138. Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents

142. Myopia and Early-Onset Type 2 Diabetes: A Nationwide Cohort Study.

143. Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood

144. Cardiorenal outcomes with dapagliflozin by baseline glucose‐lowering agents: Post hoc analyses from DECLARE‐TIMI 58

147. Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel

150. 278-OR: Efficacy and Safety of Anti-interleukin (IL)-21 in Combination with Liraglutide in Adults Recently Diagnosed with Type 1 Diabetes

Catalog

Books, media, physical & digital resources